Rhinitis, Allergic, Seasonal — Allergen Challenge Chamber Study With Single Dose Oral GSK835726 Compared With Placebo
Citation(s)
A Randomised, Double-blind, Placebo-controlled, 4-period Incomplete Block Crossover Study of Single Oral Dose GSK835726 (100mg, 50mg, 10mg), Cetirizine (10mg) and Placebo to Evaluate the Efficacy and Safety Using an Environmental Challenge Chamber in Male Subjects With Seasonal Allergic Rhinitis